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(WOS), (2) the number of citations in WOS, (3) the Hirsch 
index and (4) the contribution as a first author (or shared 
first author).
Based on a combination of these results, the jury finally 
selected three nominees: K.Y. van Spaendonck-Zwarts (Uni-
versity Medical Centre Groningen), N.M. van Mieghem 
(Erasmus Medical Centre, Rotterdam) and W.J. Dewilde 
(Sint Antonius Hospital, Nieuwegein).
The members of the jury were: J.W. Deckers (Director 
CVOI), S. Heymans (ICIN professor), A. Mosterd (Chair-
man WCN), M.J. Schalij (Chairman Concilium NVVC) and 
V.A. Umans (President NVVC).
The three candidates presented their Ph.D. theses at the 
annual spring meeting of the NVVC, held at the Congress 
Centre “De Leeuwenhorst” in Noordwijkerhout, 9–10 April 
2015. Based on the quality of the presentation, the audience 
determined the ranking of the laureates. Mrs. dr. K.Y. van 
Speandonck-Zwarts received the third prize, dr. N.M. van 
Mieghem the second prize, and dr. W.J. Dewilde the first 
prize. We like to congratulate the three winners with their 
excellent PhD Theses. Summaries of the three nominated 
PhD theses are given below.
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Abstract
For the 26th time in a row the Interuniversity Cardiology 
Institute of the Netherlands (ICIN-Netherlands Heart Insti-
tute) and the Netherlands Society of Cardiology (NVVC) 
have supported the competition for the best three cardio-
vascular PhD theses, published in the year 2014 [1–3]. The 
dissertation prize carries the name of one of the greatest 
Dutchmen in the history of cardiovascular medicine, Wil-
lem Einthoven, who in 1902 for the first time recorded the 
human ECG, for which he received the Nobel Prize in 1924 
[4].
This time the jury received a total of 28 PhD disserta-
tions published in 2014. The jury members were very much 
impressed by the high scientific quality of the PhD fellows. 
The ultimate selection was based on a combination of sev-
eral parameters: the curriculum vitae of the candidate, the 
scientific originality of the PhD thesis and its relevance for 
the cardiovascular field. In addition, several objective bib-
liometric parameters were used: (1) the number of articles 
in first-rate journals both in PubMed and the Web of Science 
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Summary
Inherited cardiomyopathies: genetics and gene-
environment interactions
In the last two decades, there have been significant break-
throughs in unraveling genetic factors underlying inherited 
cardiomyopathies. This is especially important for the rela-
tives of patients with cardiomyopathies. Timely diagnosis 
of cardiomyopathies and identifying individuals at risk pro-
vide the possibility of preventing complications and reduc-
ing morbidity and mortality.
Dilated cardiomyopathy (DCM) is highly heterogeneous 
and shows clinical and genetic overlap with other cardiomy-
opathy subtypes. In some cases, it may occur with neuromus-
cular involvement. An overview of 10 years experience with 
genetic analysis in a large well-defined cohort of idiopathic 
DCM patients (n = 418) shows that clinical clues, such as 
associated neuromuscular disease or signs of familial occur-
rence, can strongly increase the yield of genetic analysis in 
DCM. A PLN founder mutation and LMNA mutations were 
most prevalent and often demonstrated a specific phenotype. 
One of the numerous (> 50) known DCM-related genes is the 
DES gene. DES mutations cause desmin-related myopathy, 
an inherited skeletal and cardiac myopathy. A meta-analysis 
of reported DES mutation carriers (n = 159 with 40 differ-
ent mutations) showed that 50 % of carriers exhibited both 
neurological and cardiological signs, and strikingly nearly a 
quarter of carriers exhibited isolated cardiological signs. The 
cardiac phenotype of two founder DES mutations (p.S13F 
and p.N342D) is characterised by cardiomyopathy and car-
diac conduction disease and/or arrhythmias. There are indi-
cations that ICD therapy is better than pacemaker therapy for 
DES mutation carriers who are in need of a pacemaker. New 
genomic techniques, such as next-generation sequencing, 
now make it possible to analyse larger numbers of genes, 
even the entire exome or genome, quickly and at reasonable 
cost. This facilitated the discovery of the genetic cause of an 
autosomal recessive lethal form of cardioskeletal myopathy. 
Several Dutch families have children who died with this dis-
order due to a founder MYL2 mutation (c.403–1G > C).
Increasing the knowledge on gene-environment interac-
tions is critically important for clinical practice. We have 
shown that a subset of cases with peripartum cardiomyopa-
thy (PPCM) is part of familial DCM, whereas previously 
PPCM was classified as a non-genetic, non-familial form 
of DCM. Hence cardiological screening for covert DCM 
in first-degree relatives of PPCM patients is advisable, and 
cardiological screening during pregnancy and puerperium 
should be considered for first-degree relatives (or relatives 
carrying an underlying mutation) of familial DCM patients. 
Targeted next-generation sequencing demonstrated that 
mutations in cardiomyopathy-related genes, especially in 
TTN, are common in families with both PPCM and DCM. 
Full and larger-scale analysis of this gigantic gene only 
recently became available through next-generation sequenc-
ing. Presence of an underlying mutation or positive family 
history for cardiomyopathy in a PPCM patient may be a 
prognostic factor for low recovery rate. A second hitherto 
unknown gene-environment interaction in inherited cardio-
myopathies is chemotherapy. We have shown that familial 
predisposition for DCM can be a risk factor for anthracy-
cline-associated cardiomyopathy (AACM). Five DCM fam-
ilies with one AACM patient, and one AACM patient with 
family members with previously unrecognised early signs 
of DCM were identified. Moreover, in two of these six fami-
lies we confirmed the genetic nature of the disease by identi-
fying pathogenic MYH7 mutations. Thus, prior to treatment 
of a cancer patient with anthracyclines, careful evaluation of 
the family history for cardiomyopathy is advisable. The two 
examples above show highly penetrant genetic factors that 
are influenced by environmental factors. If we extrapolate 
this for less penetrant genetic factors, we can speculate that 
these play a role in pathomechanisms of numerous, higher 
prevalent cardiovascular diseases.
K. van Spaendonck-Zwarts
Academic Medical Centre Amsterdam
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Summary
Transcatheter aortic valve implantation-from cutting 
edge to mainstream
Over the last decade, transcatheter aortic valve implantation 
(TAVI) has become an established treatment for selected 
patients with symptomatic severe aortic stenosis. The scope 
of this PhD thesis was to provide novel insights into (1) 
refined TAVI-tailored risk stratification, (2) importance of 
uniform reporting, (3) procedural complications and longer-
term outcome and (4) strategies to improve TAVI results.
Risk stratification for aortic stenosis patients has evolved 
considerably. The integrated multidisciplinary heart team 
has replaced conventional surgical models to ultimately 
assess an individual’s operative risk and determine the best 
treatment strategy.
Accurate understanding of TAVI-related complications 
would help push this novel technology forward. The Valve 
Academic Research Consortium (VARC) was a collabora-
tive effort of academic institutions, research organisations, 
competent authorities and industry stakeholders and pro-
posed standardised consensus definitions for TAVI-specific 
clinical endpoints. Its adoption by the clinical community 
allowed a more reasonable comparison of reported clinical 
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these patients have to undergo percutaneous coronary inter-
vention (PCI), additional dual antiplatelet treatment with 
aspirin and a P2Y12 inhibitor becomes indicated to prevent 
stent thrombosis. In a rapidly ageing community, the num-
ber of patients suffering from both AF and CAD is steadily 
increasing. Up to 2012 these patients were treated with ‘tri-
ple therapy’ which is the combination of aspirin, clopido-
grel and a vitamin K antagonist (VKA). However, this triple 
therapy also has its downsides. There is an association with 
an annual bleeding risk of up to 45 % and bleeding is the 
Achilles heel of triple therapy because it is associated with 
an increased mortality risk.
This thesis is based upon the clinical problem in this 
high-risk patient group (AF and PCI) that we encountered 
in 2007–2008 when patients had a high bleeding tendency 
when treated with triple therapy. We set out to decrease the 
bleeding risk without increasing the risk of stent thrombo-
sis. In this thesis, we provide evidence that suggests that 
the increased bleeding risk outweighs the efficacy (prevent-
ing stent thrombosis, myocardial infarction (MI), stroke and 
thromboembolism) benefit of triple therapy in these patients 
and we present a possible new strategy of VKA and a P2Y12 
inhibitor alone.
Also, in this thesis we have tried to highlight all aspects 
of performing PCI in patients with long-term OAC, begin-
ning with the investigation of the optimal peri-procedural 
regimen (bridging or not?). Furthermore, we paid attention 
to optimising stent choice (drug eluting or bare metal stent) 
and investigated a possible interaction in the hepatic cyto-
chrome P450 system of both the metabolism of clopidogrel 
and acenocoumarol. We conclude with a critical appraisal in 
which the strengths and the weaknesses of the WOEST trial 
(What is the Optimal antiplatElet and anticoagulant therapy 
in patients with oral anticoagulation and coronary StenT-
ing trial) are highlighted and we comment on new evidence 
backing up the results of the WOEST trial. We address 
important unanswered questions such as the use of the new 
direct oral anticoagulants in PCI, the optimal duration of 
clopidogrel treatment, the use of other P2Y12 inhibitors and 
whether the optimal treatment after stopping clopidogrel is 
OAC or the combination of OAC and aspirin.
We conclude and recommend consideration of the only 
combination (OAC and clopidogrel) that has shown favour-
able results as compared with the recommended triple ther-
apy in AF patients undergoing PCI.
W. Dewilde
Interventional Cardiology, Amphia Hospital, Breda
Email: willemdewilde@yahoo.com
Open Access This article is distributed under the terms of the Creative 
Commons Attribution License which permits any use, distribution, and 
reproduction in any medium, provided the original author(s) and the 
source are credited.
data. The bulk of major vascular complications after TAVI 
seem related to artery closure device failure. New closure 
designs and alternative access strategies could help reduce 
access site complications. Conduction disorders are fre-
quent after TAVI, especially with self-expanding designs. In 
approximately half of the cases, conduction abnormalities 
seem to occur following balloon pre-dilatation prior to the 
transcatheter valve implantation per se. Furthermore, over 
half of the patients who received a permanent pacemaker 
after TAVI were no longer pacemaker dependent after 1 
year. Clearly device selection, avoidance of balloon dilata-
tion and a watchful waiting approach may lower pacemaker 
rates after TAVI. Neurological events after TAVI predomi-
nantly occur within the first 24 hours of the procedure and 
seem directly related to invasive manipulations and sub-
optimal anticoagulation. Indeed, we analysed the content 
of embolic protection filters that had been deployed in the 
extracranial vessels during TAVI and found macroscopic 
debris in 75 % of all patients. Debris stemmed from the 
aortic wall or aortic valve in 52 % of cases and thrombotic 
material was identified in half of the patients. These insights 
highlight the importance of minimising the instrumentation 
within the vascular tree during TAVI, improved and more 
reliable per-procedural anticoagulation and potential ben-
efits of cerebral embolic protection devices.
Multi-centre registry data confirmed the impact of learn-
ing curve and growing proficiency as TAVI was performed 
with gradually less major vascular and life-threatening 
bleeding complications and with improved 1-year survival. 
Importantly, similar clinical outcome was achieved with dif-
ferent transcatheter valve platforms.
In conclusion, this thesis dove into the specifics of patient 
selection and clinical outcome with TAVI and has reached 
out to novel developments that could further improve its 
practice. Refinements are essential for TAVI to become a 
safe and durable alternative to surgical aortic valve replace-
ment in a broader set of patients with lower operative risk 
and preserved life expectancy.
N.M. Van Mieghem
Interventional cardiology, 
Thoraxcentrum Erasmus Medical Centre, Rotterdam
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Summary
Optimal antiplatelet and anticoagulant therapy in 
patients with oral anticoagulation and coronary stenting
Chronic oral anticoagulation (OAC) is necessary in patients 
with mechanical heart valves and in most patients with 
atrial fibrillation (AF). A large subgroup of these patients 
has concomitant coronary artery disease (CAD). In case 
